메뉴 건너뛰기
Oncologist
Volumn 13, Issue 6, 2008, Pages 734-735
18F-fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma
Author keywords

[No Author keywords available]
Indexed keywords

FLUORODEOXYGLUCOSE F 18; SORAFENIB; BENZENESULFONIC ACID DERIVATIVE; DIAGNOSTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; VASCULOTROPIN RECEPTOR;
EID: 46149126409     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0063     Document Type: Letter
Times cited : (17)
References (7)
  • 1
    • 38049092935 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: The role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy
    • O'Neil BH, Venook AP. Hepatocellular carcinoma: The role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. The Oncologist 2007;12:1425-1432.
    • (2007) The Oncologist , vol.12 , pp. 1425-1432
    • O'Neil, B.H.1    Venook, A.P.2
  • 2
    • 33749017926 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    • Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
    • (2006) J Clin Oncol , vol.24 , pp. 4293-4300
    • Abou-Alfa, G.K.1    Schwartz, L.2    Ricci, S.3
  • 3
    • 34548720158 scopus 로고    scopus 로고
    • Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    • Llovet J, Ricci S, Mazzaferro V et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25(suppl 18):1.
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18 , pp. 1
    • Llovet, J.1    Ricci, S.2    Mazzaferro, V.3
  • 4
    • 4544313522 scopus 로고    scopus 로고
    • Recent advances in imaging hepatocellular carcinoma: Diagnosis, staging and response assessment: Functional imaging
    • Hain SF, Fogelman I. Recent advances in imaging hepatocellular carcinoma: Diagnosis, staging and response assessment: Functional imaging. Cancer J 2004;10:121-127.
    • (2004) Cancer J , vol.10 , pp. 121-127
    • Hain, S.F.1    Fogelman, I.2
  • 5
    • 34347273385 scopus 로고    scopus 로고
    • Positron emission tomography/computer tomography: Challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies
    • Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: Challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007;13:2775-2783.
    • (2007) World J Gastroenterol , vol.13 , pp. 2775-2783
    • Sun, L.1    Wu, H.2    Guan, Y.S.3
  • 6
    • 33746078149 scopus 로고    scopus 로고
    • 18F-FDG-PET as a candidate for "qualified biomarker": Functional assessment of treatment response in oncology
    • 18F-FDG-PET as a candidate for "qualified biomarker": Functional assessment of treatment response in oncology. J Nucl Med 2006;47:901-903.
    • (2006) J Nucl Med , vol.47 , pp. 901-903
    • Larson, S.M.1    Schwartz, L.H.2
  • 7
    • 38849182399 scopus 로고    scopus 로고
    • Application of PET/CT in the development of novel anticancer drugs
    • Boss DS, Olmos RV, Sinaasappel M et al. Application of PET/CT in the development of novel anticancer drugs. The Oncologist 2008;13:25-38.
    • (2008) The Oncologist , vol.13 , pp. 25-38
    • Boss, D.S.1    Olmos, R.V.2    Sinaasappel, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.